STUDY QUESTION: Is random start ovarian stimulation associated with delays in initiation of neoadjuvant chemotherapy for breast cancer?
Introduction
Chemotherapy for breast cancer has been associated with infertility and early menopause (Partridge et al., 2007; Letourneau et al., 2011b) . Such detrimental effects on reproductive health have been associated with decreased quality of life among survivors of breast cancer (HowardAnderson et al., 2012) . Having the ability to discuss one's future reproductive potential prior to chemotherapy, as well as the ability to freeze oocytes or embryos for future use, have been associated with improvements in quality of life (Letourneau et al., 2011a; Deshpande et al., 2015) .
Neoadjuvant chemotherapy is now a widely accepted treatment modality for operable breast cancer. Neoadjuvant chemotherapy offers the benefit of potentially improved cosmesis and provides an opportunity to assess histologic tissue response to chemotherapeutic agents (Ahn et al., 2015) . Although adjuvant chemotherapy remains the most common breast cancer treatment, neoadjuvant chemotherapy is becoming more popular, with an estimated ten percent of chemotherapy now given in the neoadjuvant setting (Graham et al., 2015) . The adjuvant treatment setting allows for more time to achieve oocyte or embryo cryopreservation because diagnosis is followed by surgery, post-surgical recovery, and, finally, chemotherapy (Baynosa et al., 2009) . In the neoadjuvant setting, however, diagnosis immediately precedes chemotherapy, creating an apparent time pressure to complete the fertility preservation (FP) process. The American Society of Clinical Oncology recommends referral to a fertility specialist prior to gonadotoxic cancer treatment, such as neoadjuvant chemotherapy, in reproductive age women (Loren et al., 2013) . The increased popularity of neoadjuvant chemotherapy necessitates a focus on how to most efficiently complete FP consultation and oocyte retrieval while minimizing cancer treatment delays.
A 2009 study demonstrated that conventional start ovarian stimulation, which can take up to 4-6 weeks to complete a single cycle of egg or embryo freezing, because the ovarian stimulation start is timed with the onset of next menses, does not appear to delay the onset of adjuvant chemotherapy for breast cancer (Lohrisch et al., 2006; Baynosa et al., 2009; Gagliato et al., 2014) . Over the last several years, however, there have been significant advances in ovarian stimulation techniques in an urgent setting, with studies showing that stimulations can start at any random point in the menstrual cycle with equal outcomes (Cakmak et al., 2013; von Wolff et al., 2016) . Consequently, without the need to wait for the onset of next menses, egg or embryo cryopreservation can technically be accomplished within 2 weeks of consult. In the setting of neoadjuvant chemotherapy treatment, this method of 'random start' ovarian stimulation may minimize delays. While delays in the initiation of neoadjuvant chemotherapy are not yet known to affect oncological outcomes, a perceived delay in therapy can cause distress for patients and providers (Gold et al., 2016) .
Starting in 2011, all patients in our FP center who planned to undergo neoadjuvant chemotherapy were treated with random start ovarian stimulation if they chose to freeze oocytes or embryos. To determine whether random start ovarian stimulation is associated with delays in the onset of neoadjuvant chemotherapy, we performed a record review on this population.
Materials and Methods
We performed a cross-sectional study. All study procedures were approved by University of California, San Francisco (UCSF) Committee on Human Research.
FP consultation
Our patients were referred from regional oncology centers for FP consultation after they were diagnosed with breast cancer. At the initial FP consultation, we assessed ovarian reserve by measuring antral follicle count (AFC). Using a combination of AFC, patient age and population-based expectations for post-chemotherapy reproductive health outcomes, patients were informed of an estimate of their post-chemotherapy reproductive potential (Letourneau et al., 2011b) . Some patients then decided to undergo ovarian stimulation for FP while some did not. Every patient who chose to freeze eggs or embryos underwent a random start, antagonist-based, ovarian stimulation cycle and egg retrieval. All patients with estrogen receptor positive cancer received Letrozole or Tamoxifen for estrogen modulation during ovarian stimulation.
Study population
An electronic chart-review was performed to select all patients from our clinic who had undergone evaluation for FP from January of 2011 through April of 2017. January of 2011 was chosen as the beginning of the study because that was when we began to routinely utilize random start ovarian stimulation. Inclusion criteria included being age 18-45 years old at FP consultation, having a recent non-metastatic breast cancer diagnosis with upcoming neoadjuvant chemotherapy, and having been seen for FP consultation. Patients were excluded if they had metastatic breast cancer or did not ultimately undergo neoadjuvant chemotherapy. We categorized patients who were seen for FP consultation into those who did undergo ovarian stimulation to cryopreserve oocytes or embryos and those who did not. We recorded various demographic and cancer history characteristics for each patient. Clinical cancer stage was defined by tumor size and node status on diagnostic imaging. 
Statistical analysis
Electronic medical record data were extracted and de-identified. Statistical analyses were performed using Stata version 14 (Stata Corp, College Station, TX). Statistical significance was defined by two-sided P-values of <0.05. T-tests and proportion tests were used to compare demographic and cancer history characteristics. Descriptive statistics and t-tests were used to compare time-points from cancer diagnosis to chemotherapy. We identified cancer history or demographic characteristics that were significantly different (P < 0.05) between those who did and did not undergo ovarian stimulation. These significantly different characteristics were then included in a general linear model to evaluate for confounding upon average time from diagnosis to chemotherapy.
Results
Eighty-nine patients met inclusion criteria. Complete chemotherapy and FP records were available for 87 (98%) of these patients. Fiftyeight women (67%) underwent at least one cycle of ovarian stimulation for FP. Two of the 58 women underwent two cycles of ovarian stimulation prior to chemotherapy start. Twenty-nine women (33%) did not undergo ovarian stimulation. Women who underwent ovarian stimulation were younger than women who did not (33.7 ± 4.5 versus 37.1 ± 4.4 years, P = 0.001). Women who did and who did not undergo ovarian stimulation were similar in terms of: AFC, prior parity, clinical cancer stage and hormone receptor status (Table I) . Patients referred from within our university system underwent ovarian stimulation 76% of the time, whereas that those referred from a regional cancer center outside the university did so at lower rate of 52% (P = 0.019). Referral from outside the university system did not result in longer delays from cancer diagnosis to FP consultation or from last visit with an FP provider to the start of chemotherapy (Supplementary Table SI) .
Those who underwent ovarian stimulation had an average of 21.1 ± 11.3 oocytes retrieved (Table II) . Ovarian stimulation lasted an average of 12.4 ± 1.7 days and was associated with average peak estradiol levels of 1560 ± 1322 pg/ml. Women with Estrogen Receptor positive breast cancer had lower peak estradiol, given Letrozole use, with an average of 889 ± 655 pg/ml. Twenty-four women chose to freeze Day 3 embryos and had an average of 10.3 ± 5.1 embryos frozen.
Those who did not undergo ovarian stimulation were referred for FP consultation an average of 9 days later than those women who did undergo ovarian stimulation (17.9 ± 15.3 versus 9.4 ± 6.8 days, P < 0.001; Table III ). The time from initial FP consult to chemotherapy start was slightly shorter in the group that did not undergo ovarian stimulation (17.7 ± 13 versus 25.2 ± 8.4 days, P = 0.002). During this time from FP consult to chemotherapy start, women who did undergo ovarian stimulation spent an average of 3.9 ± 4.9 days preparing to start ovarian stimulation and another 12.7 ± 2.5 days undergoing ovarian stimulation. However, after completing their care with the FP clinic, women who underwent ovarian stimulation started chemotherapy within an average of 8.4 ± 6.2 days. This is 9 days shorter than the This estradiol value reflects all women in the study. Women with Estrogen Receptor positive breast cancer had lower peak estradiol (due to Letrozole use) with an average of 889 ± 655 pg/ml at peak on the day of trigger. We generally titrate letrozole throughout the cycle to keep estradiol levels below 500 pg/ml. The average peak estradiol levels were higher than 500 pg/ml in the Estrogen Receptor positive breast cancer group because we used Tamoxifen for estrogen modulation in some cycles, rather than Letrozole.
time from last FP clinic visit (their initial FP consultation) to chemotherapy start among those who did not undergo ovarian stimulation (8.4 ± 6.2 versus 17.7 ± 12 days, P < 0.001) (Table III) . While the average time from diagnosis to chemotherapy is similar in both groups, individuals appear to differ in the amount of time spent in various phases of FP care (Fig. 1) .
Overall, the average time from cancer diagnosis to chemotherapy was similar between the group that did undergo ovarian stimulation and those who did not (38.1 ± 11.3 versus 39.4 ± 18.5 days, P = 0.672; Table III ). This relationship continued to lack a significant difference after controlling for the effect of age and referral center (inside or outside of the same university) (Linear model coefficient = −1.82, P = 0.615). The average time spent in the ovarian stimulation process was 12.7 ± 2.5 days, including two patients who underwent a second cycle of ovarian stimulation. The first cycle of ovarian stimulation, amongst all who underwent ovarian stimulation, lasted an average of 12.4 ± 1.6 days. Two patients underwent a second cycle of ovarian stimulation due to diminished ovarian reserve. In order to better meet their future family-building goals, a second cycle was attempted in each case. The average time from the first cycle's oocyte retrieval to the second cycle's ovarian stimulation start was 4.5 ± 6.4 days. The average length of the second cycle was 9 ± 7.1 days. The time from diagnosis to chemotherapy in the two patients who underwent two cycles was 43.5 ± 10.6 days.
Discussion
In the neoadjuvant setting, where time to chemotherapy is shortened as compared to the adjuvant setting, ovarian stimulation can be successfully performed. Using random start ovarian stimulation, we were able to complete ovarian stimulation and oocyte retrieval within approximately two weeks. Among women who complete FP consultation, random start ovarian stimulation is unlikely to delay time to initiation of neoadjuvant chemotherapy start.
We observed that patients in the ovarian stimulation group and the no ovarian stimulation group each took an average of 5-6 weeks to start neoadjuvant chemotherapy. Naturally, this timing may reflect unmeasured aspects of care within our referral network, including: patient decision-making time, the number of second-and third opinions sought, and varying extents of pre-treatment imaging and biopsies (Bleicher et al., 2012) . Such aspects of care may also explain, at least in part, why women who did not undergo ovarian stimulation still took 18 days to start chemotherapy after their FP consult. In other words, chemotherapy may not have started immediately because their cancer work-up and oncology plan was being completed. Some time is inherently bound to pass as patients come to understand their diagnosis and become comfortable with their oncology treatment plan. So, a window appears to remain for ovarian stimulation to be conducted without significant treatment delays.
There are few studies examining the importance of the time interval from diagnosis to neoadjuvant chemotherapy start, and no prospective trial can ethically subject patients to intentional delays to determine a threshold for harm (Bleicher et al., 2012) . Data from the California Cancer Registry shows no decrease in 5-year survival among those who began neoadjuvant chemotherapy up to 6 weeks post-diagnosis (Smith et al., 2013) . Currently unpublished data reported at the 2016 American Society of Clinical Oncology (ASCO) meeting showed that a delay of greater than 9 weeks between diagnosis and neoadjuvant chemotherapy initiation is associated with a decrease in 5-year overall survival (86% versus 81%) (Sanford et al., 2016) . In the ASCO meeting report, the median time from diagnosis to neoadjuvant chemotherapy start was~5 weeks. In the California Cancer Registry study mentioned above, the median time from diagnosis to neoadjuvant chemotherapy was 3-4 weeks. The average time to neoadjuvant chemotherapy start in our study of 5-6 weeks was slightly longer than the two previously mentioned studies. This slight increase in time from diagnosis to chemotherapy could be related to unmeasured factors in this reproductive age, urban population, such as multiple consultations and variable decision time regarding cancer treatment options. There are no data, however, to suggest that this difference would affect cancer outcomes. Nonetheless, as patients, oncologists, and FP providers are eager for chemotherapy to begin, and as the future could call for a push for an earlier onset of chemotherapy, future work should continue to be aimed at making the FP process as efficient as possible.
We reported on patients who underwent random start ovarian stimulation. The median time from FP referral to oocyte retrieval was 32 days in the previously mentioned conventional start study in the adjuvant setting (Baynosa et al., 2009) . Using random start ovarian stimulation, our time from FP referral to oocyte retrieval was 12 days shorter than the in the adjuvant chemotherapy study, which used conventional start ovarian stimulation. Additionally, for two of the patients, we were able to complete two random start ovarian stimulation cycles, without significant delays in chemotherapy initiation.
While random start is not a conventional way to stimulate infertility patients, there have been several studies to support its efficacy. Previous work in our center has examined ovarian stimulation outcomes between random start and conventional start ovarian stimulation. This work showed similar total oocyte yields, mature oocyte yields, and fertilization rates between conventional start and random start (Cakmak et al., 2013) . Recently, others have also noted similar outcomes after initiating ovarian stimulation during any phase of the menstrual cycle, supporting the concept of random start ovarian stimulation (von Wolff et al., 2016) .
While the patients who did undergo random start ovarian stimulation had acceptable FP outcomes in this study, we should also focus on those who did not undergo ovarian stimulation and on those who did not attend a FP consultation. Those in our study who underwent FP consult but who did not undergo ovarian stimulation experienced a longer delay in time from diagnosis to FP referral. Whether this delay was associated with less patient interest in FP or whether the delay in referral created an apparent time pressure that led to electing to not undergo FP is uncertain. Either way, the time from diagnosis to FP referral likely remains modifiable and improvable. Shortening the time from diagnosis to FP referral may be especially important among those women with diminished ovarian reserve, where a double-stimulation may be possible to help increase oocyte or embryo yield, to allow for a second cycle without delaying chemotherapy. Encouraging other healthcare providers, including nurses, social workers and patient navigators, to initiate the FP consult may be one method of shortening the time from diagnosis to FP referral (Bann et al., 2015) . Our study population came from regional referral centers and we unfortunately do not have access to information about which patients were not referred for FP from many of these centers. However, recent data from Chien et al. suggests that the average time from diagnosis to neoadjuvant chemotherapy among those who did not undergo FP consult was 40 days (Chien et al., 2017) .
Strengths and Limitations
This study is limited by its retrospective nature and the potential for selection bias. Such bias could result in unmeasured differences among those who did and did not undergo ovarian stimulation, in terms of patients' and providers' perceptions of the urgency to start chemotherapy. However, the relatively large number of patients and the variety of referral centers from which patients were sent for FP consultation strengthens this study and may mitigate selection bias. While FP in the neoadjuvant chemotherapy setting appears safe, more data from other investigators are needed to corroborate these findings and to explore the relationship between delay in neoadjuvant chemotherapy start and long-term cancer outcomes (Chien et al., 2017) . Until outcomes data support a specific problematic timing threshold, the reader must make a judgment about whether potential delays in neoadjuvant chemotherapy are clinically meaningful.
The difference in time from referral to FP consultation may have influenced patients' decisions about whether to undergo ovarian stimulation. There could be many factors, which were unmeasured in this study, that lead to a delay in time from diagnosis to FP referral and which may also in turn influence the decision to undergo ovarian stimulation, including: ongoing oncology work-up and treatment planning, second and third opinions for oncology and FP care, patient and provider decision-making about whether to pursue FP, and patients weighing the cost of FP (which is often not covered by insurance). Some of these unmeasured factors may have also resulted in a prolonged time from last contact with the FP to chemotherapy in the group that did not undergo ovarian stimulation. Future studies should focus on the influence of factors, such as second opinions and patient or provider decision-making, which could affect the timing of chemotherapy start in the FP setting. Future studies could also evaluate random start stimulation after use of ovarian reserve markers other than AFC, such as AMH. However, in order to begin random start stimulation as soon as possible after FP consultation, serum lab results that inform ovarian stimulation regimens should be available promptly. In the absence of these labs, we view AFC as a timely assessment of ovarian reserve, which, despite inter-operator variability, does correlate well with oocyte yield and helps to set expectations for patients in the random start setting (Fleming et al., 2015; Kotanidis et al., 2016; Moon et al., 2016) .
Conclusion
FP is becoming more common and so too is neoadjuvant chemotherapy. In the neoadjuvant setting, random start ovarian stimulation offers the advantage of shortened time from initial fertilization preservation consult to egg retrieval. However, early referral for FP remains paramount, as earlier referral may lessen a perceived time pressure for patients and providers. Among those considering FP in the setting of neoadjuvant chemotherapy for breast cancer, providers can reassure patients that random start ovarian stimulation appears unlikely to significantly delay the start of their chemotherapy.
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